TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01267838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: PCI of bifurcation lesions with double stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: PCI of bifurcation lesions with double stenting
Study: NCT02793427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample collection
Study: NCT03049436

Intervention type: OTHER
Intervention: Program of adapted physical activity
Study: NCT01348087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
Study: NCT01532232

Intervention type: DRUG
Intervention: placebo
Description: Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.

Intervention type: DRUG
Intervention: varenicline
Description: Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy \& equivalent dosing \& side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians \& tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
Study: NCT02023372

Intervention type: OTHER
Group type: OTHER
Intervention: NuCel with Autograft
Description: NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
Study: NCT02785978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa acute challenge
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled environment tests (series of tasks of everyday life)
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled environment tests (series of tasks of everyday life)
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled environment tests (series of tasks of everyday life)
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized scales: MDS-UPDRS (Part II to IV) and RDRS
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiMyo recording
Description: Continuous activity recording with ActiMyo during the 2 weeks of study participation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiMyo recording
Description: Continuous activity recording with ActiMyo during the 2 weeks of study participation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiMyo recording
Description: Continuous activity recording with ActiMyo during the 2 weeks of study participation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary completion
Description: Daily patient logbook completion during the 2 weeks of study participation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary completion
Description: Daily patient logbook completion during the 2 weeks of study participation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary completion
Description: Daily patient logbook completion during the 2 weeks of study participation
Study: NCT03705819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-NOP46
Description: Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-NOP46
Description: Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: After subjects receive a microdose of \[11C\]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
Study: NCT04362501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: 300mg dupixent SC every two weeks for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo SC injection every two weeks for six months
Study: NCT03503773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: endovascular, renal angiography
Study: NCT03603418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Distilled water
Study: NCT03620929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
Study: NCT00782639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol injection 76%
Description: Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iodixanol
Description: Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
Study: NCT03183024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: benralizumab
Description: open-label treatment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile water to mimic benralizumab
Study: NCT02621593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22-IPL
Description: The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
Study: NCT04743128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The experimental group started an exercise program to achieve 65% to 80% of the maximum heart rate by using a pulsometer that measured the heart rate in order to get to the moderate intensity activity goal. The exercise session was 60 minutes long, three times per week, completing 180 minutes per week of moderate intensity exercise, for 12 weeks in total.
Study: NCT04118374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Carb Diet
Description: Approximately 50% of caloric intake will come from carbohydrate consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Carb Diet
Description: Approximately 50% of caloric intake will come from carbohydrate consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb Diet
Description: Approximately 25% of caloric intake will come from carbohydrate consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb Diet
Description: Approximately 25% of caloric intake will come from carbohydrate consumption.
Study: NCT00281918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose
Study: NCT03964285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rumination induction
Description: The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction induction
Description: The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
Study: NCT04168814

Intervention type: OTHER
Intervention: Observational test
Description: Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.

Intervention type: OTHER
Intervention: Observational test
Description: Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site. Covid-19 diagnosis.
Study: NCT03917329

Intervention type: OTHER
Group type: OTHER
Intervention: ACT and PBS group workshop
Description: Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
Study: NCT02157493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arrowhead Business Group Curriculum
Description: Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational League Control Condition
Description: The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational League Control Condition
Description: The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
Study: NCT04784741

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional static hamstring muscle stretching
Description: Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low amplitude whole body vibration therapy
Description: Given five sessions of low amplitude whole body vibration therapy for duration of 10 minutes, on alternative days, along with static stretching of hamstring muscles.~Static stretching protocol had 10 repetitions in total with 15 seconds stretch time and 30 seconds relaxing time of hamstring muscle.

Intervention type: DEVICE
Group type: OTHER
Intervention: Biodex Balance System
Description: Pre and post balance assessment by Biodex balance system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex Balance System
Description: Pre and post balance assessment by Biodex balance system

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Range of motion of hamstring muscle
Description: Straight Leg Raising to check pre and post Range of Motion by using Goniometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Range of motion of hamstring muscle
Description: Straight Leg Raising to check pre and post Range of Motion by using Goniometer
Study: NCT01457222

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness intervention
Description: Web-based guided mindfulness meditation 10 minutes daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music relaxation
Description: Music relaxation 10 minutes daily
Study: NCT04464057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early oral feeding or early enteral nurtrion
Description: The patients in the experimental group were fed orally within 24-48 hours after intestinal anastomosis. Start taking it at 24-48 hours after surgery until discharged. The initial dose is 1ml/kg.h, which is gradually increased to 100ml/kg daily.
Study: NCT00995709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02113163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Eicosapentaenoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Eicosapentaenoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl and Vascepa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl and Vascepa
Study: NCT02828683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI in patients with ST-elevation myocardial infarction
Description: Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI in patients with ST-elevation myocardial infarction
Description: Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
Study: NCT02471391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT03781804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study: NCT01660204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preferred empirical treatment
Description: The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preferred empirical treatment
Description: The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
Study: NCT03781804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study: NCT01660204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preferred empirical treatment
Description: The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
Study: NCT03128827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAM sensor
Description: Acoustic Respiration Monitor
Study: NCT02364921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two multilayer compression bandage
Description: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crepe bandage
Description: Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
Study: NCT00768066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous human mesenchymal cells (hMSCs)
Description: Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous human bone marrow cells (hBMCs)
Description: Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
Study: NCT01548391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg
Study: NCT02154737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
Study: NCT01548391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg
Study: NCT02359422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware-Sexual Health
Description: 10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.